Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

93.04 +0.08 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Via ACCESSWIRE
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
From Gilead Sciences, Inc.
Via Business Wire
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts
Via Benzinga
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success... 
Via Benzinga
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Will GILEAD SCIENCES INC breakout?
Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC. 
Via Chartmill
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Via Benzinga
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact... 
Via Benzinga
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Via Benzinga
News Is Noise
Via Talk Markets
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
Top 4 Health Care Stocks That May Keep You Up At Night
Via Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. 
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.